G1 Therapeutics' GAAP loss for 3 months of 2023 was $27.595 million, down 43.9% from $49.192 million in the prior year. Revenue increased 87.6% to $12.946 million from $6.902 million a year earlier.
G1 Therapeutics' GAAP loss for 3 months of 2023 was $27.595 million, down 43.9% from $49.192 million in the prior year. Revenue increased 87.6% to $12.946 million from $6.902 million a year earlier. 
investor.g1therapeutics.com
English (US) 